Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase

Molecular Carcinogenesis

Volumn 49, Issue 7, 2010, Pages 662-671

  Hosono, Kunihiro ^a   Endo, Hiroki ^a   Takahashi, Hirokazu ^a   Sugiyama, Michiko ^a   Uchiyama, Takashi ^a   Suzuki, Kaori ^a   Nozaki, Yuichi ^a   Yoneda, Kyoko ^a   Fujita, Koji ^a   Yoneda, Masato ^a   Inamori, Masahiko ^a   Tomatsu, Akiko ^b   Chihara, Takeshi ^b   Shimpo, Kan ^b   Nakagama, Hitoshi ^c   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

AMPK; Chemoprevention; Colorectal carcinogenesis; Metformin; mTOR

Indexed keywords

AZOXYMETHANE; CHOLESTEROL; CYCLINE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; S6 KINASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; BODY WEIGHT; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLON POLYP; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; LABELING INDEX; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; AZOXYMETHANE; CELL PROLIFERATION; COLON; COLONIC POLYPS; COLORECTAL NEOPLASMS; EPITHELIAL CELLS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPIDS; METFORMIN; MICE; MICE, INBRED BALB C; PROTEIN-SERINE-THREONINE KINASES; RIBOSOMAL PROTEIN S6 KINASES;

MAMMALIA; MUS;

EID: 77954468475     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20637     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Das D, Arber N, Jankowski JA. Chemoprevention of colorectal cancer. Digestion 2007;76:51-67.
3. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21. (Pubitemid 33741877)
4. Psaty BM, Furberg CD. COX-2 inhibitors-lessons in drug safety. N Engl J Med 2005;352:1133-1135.
5. Limburg PJ, Anderson KE, Johnson TW, et al. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2005;14:133-137.
6. Larsson SC, Giovannucci E, Wolk A. Diabetes and colorectal cancer incidence in the cohort of Swedish men. Diabetes Care 2005;28:1805-1807. (Pubitemid 40923101)
7. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995;122:327-334.
8. Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut 2006;55:285-291.
9. Witters LA. The blooming of the French lilac. J Clin Invest 2001;108:1105-1107.
10. Shaw RJ, Lamina KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-1646.
11. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. Br Med J 2005;330:1304-1305.
12. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-258.
13. Corpet DE, Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:391-400.
14. Tomimoto A, Endo H, Sugiyama M, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 2008;99:2136-2141.
15. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995;93:55-71.
16. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277-1284.
17. Bergheim I, Guo L, Davis MA, et al. Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology 2006;130:2099-2112. (Pubitemid 43816952)
18. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-6752.
19. ZouMH,Kirkpatrick SS, Davis BJ, et al. Activation of theAMPactivated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 2004;279:43940-43951.
20. McLellan EA, Bird RP. Aberrant crypts: Potential preneoplastic lesions in the murine colon. Cancer Res 1988;48:6187-6192.
21. Konstantakos AK, Siu IM, Pretlow TG, Stellato TA, Pretlow TP. Human aberrant crypt foci with carcinoma in situ from a patient with sporadic colon cancer. Gastroenterology 1996;111:772-777.
22. Wilson GD, McNally NJ, Dunphy E, Karcher H, Pfragner R. The labelling index of human and mouse tumours assessed by bromodeoxyuridine staining in vitro and in vivo and flow cytometry. Cytometry 1985;6:641-647. (Pubitemid 16257697)
23. Sugihara H, Hattori T, Fukuda M. Immunohistochemical detection of bromodeoxyuridine in formalin-fixed tissues. Histochemistry 1986;85:193-195. (Pubitemid 17193675)
24. Morstyn G, Pyke K, Gardner J, Ashcroft R, de Fazio A, Bhathal P. Immunohistochemical identification of proliferating cells in organ culture using bromodeoxyuridine and a monoclonal antibody. J Histochem Cytochem 1986;34:697-701. (Pubitemid 16073400)
25. Shimazaki N, Yazaki T, Kubota T, et al. DNA polymerase lambda directly binds to proliferating cell nuclear antigen through its confined C-terminal region. Genes Cells 2005;10:705-715.
26. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): A dancer with many partners. J Cell Sci 2003;116:3051-3060.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
28. Sohn OS, Ishizaki H, Yang CS, Fiala ES. Metabolism of azoxymethane, methylazoxymethanol and N-nitrosodimethylamine by cytochrome P450IIE1. Carcinogenesis 1991;12:127-131.
29. Fiala ES, Joseph C, Sohn OS, et al. Mechanism of benzylselenocyanate inhibition of azoxymethane-induced colon carcinogenesis in F344 rats. Cancer Res 1991;51:2826-2830.
30. Herron DC, Shank RC. In vivo kinetics of O6-methylguanine and 7-methylguanine formation and persistence in DNA of rats treated with symmetrical dimethylhydrazine. Cancer Res 1981;41:3967-3972.
31. Fearon ER, Jones PA. Progressing toward a molecular description of colorectal cancer development. FASEB J 1992;6:2783-2790.
32. Chen W, Sohn OS, Fiala ES, Weisburger JH. Effect of tea on the formation of DNA adducts by azoxymethane. Xenobiotica 1998;28:213-217.
33. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.
34. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol 2005;17:158-166.
35. MamaneY, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006;25:6416-6422.
36. Aoki K, Tamai Y, Horiike S, Oshima M, Taketo MM. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice. Nat Genet 2003;35:323-330.
37. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-10273.
38. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-3586.
39. Fujisawa T, Endo H, Tomimoto A, et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 2008;57:1531-1538.